Home Cart Sign in  
Chemical Structure| 1254053-43-4 Chemical Structure| 1254053-43-4

Structure of Gilteritinib
CAS No.: 1254053-43-4

Chemical Structure| 1254053-43-4

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Gilteritinib (ASP2215) is a potent and ATP-competitive FLT3/AXL inhibitor with IC50 values of 0.29 nM and 0.73 nM, respectively.

Synonyms: ASP2215

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Gilteritinib

CAS No. :1254053-43-4
Formula : C29H44N8O3
M.W : 552.71
SMILES Code : O=C(C1=NC(CC)=C(NC2CCOCC2)N=C1NC3=CC=C(N4CCC(N5CCN(C)CC5)CC4)C(OC)=C3)N
Synonyms :
ASP2215
MDL No. :MFCD28144685
InChI Key :GYQYAJJFPNQOOW-UHFFFAOYSA-N
Pubchem ID :49803313

Safety of Gilteritinib

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Related Pathways of Gilteritinib

RTK

Isoform Comparison

Biological Activity

Target
  • FLT3

    FLT3, IC50:0.29 nM

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT06734585 Acute Myeloid Leukemia RECRUITING 2025-06-30 HK852001, Hong Kong, Hong Kong
NCT03315299 AML NO_LONGER_AVAILABLE - Children's Hospital Los Angele... More >>s, Los Angeles, California, 90027, United States Less <<
NCT06667973 Acute Myeloid Leukemia|FLT3 Ge... More >>ne Mutation|Adult AML|Diagnosis Less << PHASE2 NOT_YET_RECRUITING 2025-03-30 -
NCT05791890 Acute Myeloid Leukemia ACTIVE_NOT_RECRUITING 2024-12-31 Maria Ilaria Del Principe, Rom... More >>a, RM, 00133, Italy Less <<
NCT02561455 Advanced Solid Tumors|Acute My... More >>eloid Leukemia Less << PHASE1|PHASE2 COMPLETED 2020-07-28 Site US10005, Phoenix, Arizona... More >>, 85084, United States|Site US10003, Baltimore, Maryland, 21201, United States|Site US10006, New York, New York, 10032, United States|Site US10007, New York, New York, 10065, United States|Site US10001, Cleveland, Ohio, 44195, United States|Site US10004, Hershey, Pennsylvania, 17033, United States|Site US10008, Philadelphia, Pennsylvania, 19104, United States Less <<
NCT04699877 Renal Impaired|Gilteritinib|No... More >>rmal Renal Function|Pharmacokinetics of ASP2215 Less << PHASE1 COMPLETED 2022-07-18 National Institute of Clinical... More >> Research, Garden Grove, California, 92844, United States|Orange County Research Institute, Tustin, California, 92780, United States|Orlando Clinical Research Center, Orlando, Florida, 32809, United States|Site BG35901, Sofia, 1000, Bulgaria Less <<
NCT02571816 Hepatic Impairment|Healthy PHASE1 COMPLETED 2016-03-05 Site US10001, Miami, Florida, ... More >>33014, United States Less <<
NCT02181660 Acute Myeloid Leukemia (AML) PHASE1 COMPLETED 2016-06-27 Site JP00002, Aichi, Japan|Sit... More >>e JP00003, Fukuoka, Japan|Site JP00001, Gunma, Japan|Site JP00004, Tokyo, Japan|Site JP00005, Tokyo, Japan Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

1.81mL

0.36mL

0.18mL

9.05mL

1.81mL

0.90mL

18.09mL

3.62mL

1.81mL

Dissolving Methods
The prepared working fluid is recommended to be prepared now and used up as soon as possible in a short period of time. The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1

References

 

Historical Records

Categories